The FDA held a webinar last week regarding their recently-issued Social Media Guidance documents. Though many who registered were unable to access the webinar due to technical difficulties, the presentations slides and Q&A document were posted to the FDA website.
In reviewing the slides, there were no major revelations presented during the webinar and our original thoughts on the guidance documents are still valid:
As is often the case with regulatory direction, it seems we may learn the most from the warning letters that will follow. We’ve already seen evidence of this in the past week with the FDA’s issuance of a warning letter to a supplement company because they liked a Facebook comment that has off-label claims.
Additionally, the FDA is accepting comments and questions for the two new guidance documents on character limitations and correcting misinformation until September 16th.
Did you attend the webinar? What did you think? Let us know in the comments.
